India Pharma Outlook Team | Thursday, 09 April 2026
India has stepped up action against GLP-1 drug misuse as cheaper generic versions flood the market, raising safety concerns.
The Drugs Controller General of India has launched nationwide audits and inspections to curb GLP-1 drug misuse and protect patients.
Authorities inspected 49 entities across multiple regions, focusing on illegal sales, improper prescriptions, and misleading marketing.
Notices have already been issued, and stricter action—including license cancellations and prosecution—is expected soon. The government made it clear that these drugs must only be prescribed by qualified specialists such as endocrinologists or internal medicine experts.
Also Read: How Semaglutide Works: The Breakthrough Weight-Loss Drug
The crackdown follows a surge in generic versions of semaglutide after its patent expiry in India. Major drugmakers have entered the space, offering lower-cost alternatives that could cut treatment costs by up to 70 percent. While this improves access, it has also led to misuse, especially through wellness clinics and online sellers lacking proper medical oversight.
GLP-1 drug misuse has become a serious concern as these medications, used for diabetes and weight loss, can cause side effects if taken without supervision. Health experts warn of risks like dehydration, gallstones, and nutritional deficiencies when used improperly.
India is also facing a growing obesity crisis, with projections showing a sharp rise in overweight and obese adults by 2050. As demand for weight-loss drugs grows, regulators are tightening surveillance to ensure safety isn’t compromised.
The health ministry reiterated that strict monitoring will continue, especially after its recent advisory banning misleading promotions and off-label marketing of these drugs.
